News about "Metabolic-Associated Steatohepatitis "

UK MHRA Approves Wegovy for Treatment of MASH in Adults with Liver Fibrosis

UK MHRA Approves Wegovy for Treatment of MASH in Adults with Liver Fibrosis

The UK's Medicines and Healthcare products Regulatory Agency has conditionally approved Novo Nordisk's Wegovy (semaglutide) for treating metabolic-associated steatohepatitis (MASH) in adults with moderate-to-advanced liver fibrosis, subject to ongoing confirmatory clinical data.

Metabolic-Associated Steatohepatitis | 06/07/2026 | By News Bureau


 

 

We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.

More information: Privacy Policy

 pharmaindustrial-india.com - Professional magazine for pharma industry suppliers and lab technology - CEDRO members